Agreement Renewal
Sai Parenterals’ Australian Subsidiary Renews Exclusive OTC Supply Agreement Worth AUD 202 Million
NSE
saiparent
BSE
544742
Sai Parenterals Limited announced that its Australian subsidiary, Noumed Pharmaceuticals Pty Ltd, has renewed its exclusive OTC medicines supply agreement with one of Australia’s leading pharmacy networks. The renewed contract is valued at AUD 202 million (approximately ₹1,300 crore) over 7.5 years, with an additional 3-year extension option, significantly strengthening the company’s international pharmaceutical business and long-term revenue visibility.
PRICE-SENSITIVE TRIGGER
Event: Renewal of exclusive OTC pharmaceutical supply agreement by Australian subsidiary Noumed Pharmaceuticals.
Type: Long-term Commercial Agreement Renewal
Impact: Positive
Immediate Effect: The renewed agreement enhances Sai Parenterals’ recurring international revenues, strengthens its presence in Australia’s regulated pharmaceutical market, and improves long-term earnings visibility through an expanded product portfolio and extended contract tenure.
Key Metrics:
- Contract Value: AUD 202 million (approximately ₹1,300 crore)
- Exchange Rate Used: 1 AUD = ₹64.5
- Contract Duration: 7.5 years
- Extension Option: Additional 3 years upon mutual consent
- Average Annual Contract Value: Approximately AUD 27 million
- New Product Additions: Target of 12 new OTC products every year
- Segment Performance: International OTC pharmaceutical business expected to strengthen through the renewed agreement.
Highlight:
- Largest Commercial Highlight: Long-term OTC supply agreement valued at AUD 202 million (₹1,300 crore)with Australia’s leading pharmacy networks.
What Happened ?
Sai Parenterals announced that its Australian subsidiary, Noumed Pharmaceuticals Pty Ltd, has renewed its exclusive long-term OTC medicines supply agreement with one of Australia’s leading pharmacy retail networks.
The renewed agreement expands the product portfolio, increases the contract value, and extends the engagement to 7.5 years, with an option to extend by another three years. Effective from 1 July 2026, the agreement reinforces Noumed’s position as a preferred strategic supplier while strengthening Sai Parenterals’ international pharmaceutical footprint through predictable recurring revenues and continued expansion in regulated overseas markets.
Key Details
Commercial and Operational Highlights:
- Noumed Pharmaceuticals renewed its exclusive OTC medicines supply agreement with a leading Australian pharmacy network.
- Total agreement value stands at AUD 202 million (approximately ₹1,300 crore).
- Contract tenure has been extended to 7.5 years, with a further 3-year extension option upon mutual agreement.
- The agreement targets the launch of 12 new OTC pharmaceutical products every year, progressively increasing contract value over its life.
- Noumed will continue to manage:
- Manufacturing
- Product sourcing
- Regulatory compliance
- Therapeutic Goods Administration (TGA) registrations
- Warehousing
- Quality assurance
- Nationwide distribution
- The agreement supports expansion of Sai Parenterals’ regulated international business and enhances manufacturing scale and operational leverage.
- The renewal builds upon an established customer relationship, reflecting sustained delivery performance and regulatory trust within Australia’s highly regulated pharmaceutical market.
Note:
- The company has not disclosed the annual revenue contribution, profitability impact, or financial recognition schedule arising from the agreement.
Risk Analysis
Summary:
- The agreement provides strong long-term revenue visibility; however, financial realization will depend on execution, product launches, regulatory compliance, and customer demand throughout the contract period.
Key Risks:
- Revenue realization will occur progressively over the contract duration.
- Expansion depends on successful introduction of targeted new OTC products.
- Continued compliance with Australian pharmaceutical regulations remains essential.
- Future extension beyond 7.5 years is subject to mutual agreement.
- No financial guidance has been provided regarding margins or earnings contribution.
Worst Case:
- Delays in regulatory approvals, slower product launches, or changes in customer procurement requirements could reduce the expected commercial benefits despite the long-term contract.
Risk Level: Low
Company Commentary
- The renewal reflects Australia’s leading pharmacy networks’ continued confidence in Noumed Pharmaceuticals.
- The agreement provides sustainable and predictable long-term revenues while supporting future product launches.
- Management believes the renewal strengthens Sai Parenterals’ expansion into highly regulated international pharmaceutical markets.
- Noumed stated that the agreement demonstrates its capability to build long-term customer relationships through consistent quality, regulatory excellence, and reliable execution.
- The company expects the partnership to create long-term value for shareholders by expanding its global pharmaceutical footprint and improving earnings visibility.
Official Exchange Filing: Sai Parenterals Limited
